ISOTRETINOIN (isotretinoin) by Viatris (2) is retinoid, which when administered at the recommended dosage [see ] , inhibits sebaceous gland function and keratinization. Approved for severe recalcitrant nodular acne in non-pregnant patients 12 years of age, older with multiple inflammatory nodules with a diameter of 5 mm, greater. First approved in 2025.
Drug data last refreshed 19h ago
retinoid, which when administered at the recommended dosage [see ] , inhibits sebaceous gland function and keratinization. Clinical improvement in nodular acne patients occurs in association with a reduction in sebum secretion. The decrease in sebum secretion is temporary and is related to the dose…
Retinoid
Worked on ISOTRETINOIN at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subjects With Facial Acne.
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)
The Effect of Isotretinoin on the Etonogestrel Contraceptive Implant